My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

19.83 -0.24 (-1.21%)
Streaming Delayed Price Updated: 11:54 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
From Amarin Corporation plc
Via GlobeNewswire
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- 
From Amarin Corporation plc
Via GlobeNewswire
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Exploring Amarin Corp's Earnings Expectations
 
Via Benzinga
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Second Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
From Amarin Corporation plc
Via GlobeNewswire
Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA
Amarin Corporation (NASDAQ: AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its... 
Via Benzinga
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges
Amarin signs $175 million Vazkepa deal with Recordati, plans global restructuring and targets $70 million in cost cuts to improve cash flow 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are gapping on Tuesday?
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports First Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
From Amarin Corporation plc
Via GlobeNewswire
Top 2 Health Care Stocks That May Crash This Month
 
Via Benzinga
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday
 
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
Action Taken to Maintain Company’s Nasdaq Listing 
From Amarin Corporation plc
Via GlobeNewswire
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
– Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important... 
From Amarin Corporation plc
Via GlobeNewswire
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript
AMRN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq Listing 
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
From Amarin Corporation plc
Via GlobeNewswire
Earnings Scheduled For March 12, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.